# Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

> **NCT02188368** · PHASE2 · TERMINATED · sponsor: **Oncotherapeutics** · enrollment: 45 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** POM
- **DRUG:** Steroids
- **DRUG:** PLD
- **DRUG:** CFZ
- **DRUG:** BTZ
- **DRUG:** CLA
- **DRUG:** CY

## Key facts

- **NCT ID:** NCT02188368
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-07
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2023-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02188368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02188368, "Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02188368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*